Arena Pharmaceuticals Announces Achievement of Phase 2 Clinical Milestone Under Cardiovascular Disease Collaboration With Merck
Arena Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical trial of MK-0354, an Arena discovered orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. The Phase 2 clinical trial triggers a $4 million milestone payment to Arena under the research collaboration and license agreement for compounds targeting a G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the "good" cholesterol, similar to the therapeutic action of niacin.
The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will further evaluate safety, tolerability and pharmacokinetics, as well as potential efficacy, of MK-0354 in patients with dyslipidemia.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.